FDA: Georgia pharmacy recalling all sterile drugs

(AP)—The Food and Drug Administration says a Georgia compounding pharmacy that distributed a drug linked to eye infections is now recalling all of its injectable medicines following a federal inspection.

Clinical Specialties Compounding Pharmacy issued a recall Monday on dozens of lots of the Roche drug after receiving reports of in five patients treated with the medication. The Augusta, Ga.-based pharmacy repackages the drug in small doses to treat macular degeneration, a common vision disorder in seniors.

Avastin is approved for cancer, but many eye doctors say it is effective for macular degeneration.

The FDA said Thursday that its inspectors found issues at the pharmacy that raise questions about the sterility of its drugs. The company voluntarily agreed to recall all of its sterile products.

0 shares

Related Stories

FDA warns of another compounding pharmacy recall

date Mar 20, 2013

(AP)—The Food and Drug Administration is warning doctors that a compounding pharmacy is recalling syringes of the Roche drug Avastin after receiving reports of eye infections among patients.

FDA panel unanimously backs Regeneron eye drug

date Jun 17, 2011

(AP) -- A panel of federal health experts voted unanimously in favor of a new eye drug from Regeneron, bringing the company one step closer to competing against a blockbuster Roche drug that currently dominates the market.

Novartis tries to make UK hospitals use $1000 drug

date Apr 24, 2012

(AP) -- Drug maker Novartis says it is taking legal action in Britain to make hospitals use an eye drug that costs 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).

US warns of mold in recalled specialty drugs

date Mar 18, 2013

The U.S. Food and Drug Administration warned doctors and hospital managers Monday about a nationwide recall of all drugs made by a New Jersey compounding pharmacy because of possible mold contamination.

Recommended for you

Teva buying Auspex for $3.2 billion

date 10 hours ago

Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.

Oral hepatitis B vaccine could become a reality

date 13 hours ago

In a new study, researchers report progress toward perfecting a radical new method of producing vaccines using genetically modified corn. The approach could lead to an oral hepatitis B vaccine that requires no refrigeration ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.